Abivax (XPAR:ABVX) Accounts Payable & Accrued Expense : €48.53 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Accounts Payable & Accrued Expense?

Abivax's quarterly accounts payable & accrued expense increased from Jun. 2023 (€31.85 Mil) to Dec. 2023 (€53.29 Mil) but then declined from Dec. 2023 (€53.29 Mil) to Dec. 2024 (€48.53 Mil).

Abivax's annual accounts payable & accrued expense increased from Dec. 2022 (€17.78 Mil) to Dec. 2023 (€53.29 Mil) but then declined from Dec. 2023 (€53.29 Mil) to Dec. 2024 (€48.53 Mil).

Abivax Accounts Payable & Accrued Expense Historical Data

The historical data trend for Abivax's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Accounts Payable & Accrued Expense Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

19.40

20.76

17.78

53.29

48.53

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															16.64	17.78	31.85	53.29	48.53

Abivax Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (XPAR:ABVX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA 0RA9:UK 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.